Shingrix, the CDC preferred vaccine for shingles, is on nationwide shortage due to high demand. The manufacturer, GlaxoSmithKline (GSK), cannot make enough vaccine to fill all orders. Because of this, 麻豆学生精品版, along with other health care providers, now must limit the patient pool eligible to receive the vaccine.
Shingrix is recommended for people over the age of 50 and is delivered in two doses given two to six months apart. The limited vaccine supply currently available to 麻豆学生精品版 will be primarily given to those patients who need their second dose. Exceptions may be made for patients who have not started the vaccine and are at high risk due to an autoimmune illness or other immunocompromised conditions.
We appreciate your understanding of this supply issue. Once GSK provides adequate supplies of Shingrix we will resume providing the vaccine to all those who want to receive it.